MR-proADM: A Peptide Biomarker That Predicts Organ Failure Better Than Standard Tests

Narrative review synthesizing evidence from clinical studies on MR-proADM as a biomarker in sepsis and critical illness, comparing its prognostic performance to procalcitonin and CRP across emergency department and ICU settings.

Sepsis kills more people than heart attacks and is notoriously difficult to diagnose and monitor. Current biomarkers like procalcitonin tell you about infection but not about organ failure — which is what actually kills sepsis patients. MR-proADM fills this gap by measuring the body's vasodilatory stress response, which directly reflects how badly organs are failing. Combining PCT (infection marker) with MR-proADM (organ failure marker) could give ICU doctors a much clearer picture of disease severity and guide treatment decisions.

Adrenomedullin is one of the most potent vasodilating peptides in the body — it relaxes blood vessels, has cardiac-protective effects, and modulates the immune response. In sepsis, massively elevated adrenomedullin drives the dangerous drop in blood pressure that causes organ failure. Measuring its stable proxy (MR-proADM) gives clinicians a direct window into this pathological process. A new antibody-based therapy targeting adrenomedullin (adrecizumab) is being developed for sepsis treatment, making MR-proADM relevant as both a diagnostic and a companion biomarker.

Narrative review without systematic search methodology. MR-proADM is not yet universally available in clinical laboratories. Optimal cutoff values for clinical decision-making are not standardized. Most supporting evidence comes from observational studies rather than interventional trials that show outcomes improve when MR-proADM guides treatment. The review focuses primarily on sepsis and may overstate generalizability to other critical illnesses.